Acadia Hit With Securities Suit Over Drug Linked To Deaths
An Acadia Pharmaceuticals Inc. shareholder slapped the biopharmaceutical company with a putative securities fraud class action in California federal court Thursday, claiming the company inflated its stock price by hiding safety...To view the full article, register now.
Already a subscriber? Click here to view full article